29 studies found for:    MLN9708
Show Display Options
Rank Status Study
1 Completed A Study of MLN9708 Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: MLN9708 + Lenalidomide + Dexamethasone
Phases: Phase 1 / Phase 2
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: November 2010
Primary Completion: March 2013
2 Recruiting Proteasome Inhibitor MLN9708 in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Condition: Multiple Myeloma
Interventions: Drug: proteasome inhibitor MLN9708;   Drug: dexamethasone
Phase: Phase 2
Sponsor/Collaborators: Mayo Clinic;   National Cancer Institute (NCI)
Study Start: January 2012
Primary Completion: July 2014
3 Not yet recruiting MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
Condition: Advanced Cancers
Interventions: Drug: MLN9708;   Drug: Vorinostat
Phase: Phase 1
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
Study Start: May 2014
Primary Completion: May 2021
4 Active, not recruiting A Study of MLN9708 in Adult Patients With Lymphoma
Condition: Lymphoma
Intervention: Drug: MLN9708
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: August 2009
Primary Completion: June 2014
5 Not yet recruiting Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
Condition: Newly Diagnosed Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Lenalidomide;   Drug: Dexamethasone
Phase: Phase 2
Sponsor: Nantes University Hospital
Study Start: October 2013
Primary Completion: January 2019
6 Recruiting Phase 1 Pharmacokinetics Study of Oral MLN9708 in Patients With Advanced Nonhematologic Malignancies or Lymphoma
Conditions: Nonhematologic Malignancies;   Lymphoma
Interventions: Drug: MLN9708 Capsule B formulation;   Drug: MLN9708 Capsule A formulation;   Drug: ketoconazole;   Drug: rifampin
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: November 2011
Primary Completion: February 2015
7 Recruiting Phase 2 Study to Evaluate the Oral Combination of MLN9708 With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM)
Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide (300mg/m^2);   Drug: Cyclophosphamide (400mg/m^2);   Drug: MLN9708;   Drug: Dexamethasone
Phase: Phase 2
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: March 2014
Primary Completion: September 2016
8 Active, not recruiting Study of Oral MLN9708 in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis
Condition: Light-Chain Amyloidosis
Intervention: Drug: MLN9708
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: May 2011
Primary Completion: December 2013
9 Completed Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral MLN9708 in Adult Patients With Relapsed and Refractory Multiple Myeloma
Condition: Relapsed and Refractory Multiple Myeloma
Intervention: Drug: Oral MLN9708
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: November 2009
Primary Completion: January 2013
10 Completed Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Relapsed and Refractory Multiple Myeloma
Intervention: Drug: Oral MLN9708
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: June 2009
Primary Completion: October 2012
11 Recruiting Phase 1 Pharmacokinetic Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: MLN9708
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: December 2012
Primary Completion: June 2015
12 Recruiting MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MLN9708 + Lenalidomide + Dexamethasone;   Drug: Placebo + Lenalidomide + Dexamethasone
Phase: Phase 3
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: May 2013
Primary Completion: June 2018
13 Recruiting Pharmacokinetics Study of Oral MLN9708 Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: dexamethasone
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: September 2013
Primary Completion: August 2015
14 Recruiting MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: MLN9708;   Radiation: Questionnaires
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
Study Start: December 2012
Primary Completion: December 2017
15 Recruiting A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma
Interventions: Drug: MLN9708 + Lenalidomide + Dexamethasone;   Drug: Placebo + Lenalidomide + Dexamethasone
Phase: Phase 3
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: August 2012
Primary Completion: June 2014
16 Active, not recruiting Study of Oral MLN9708 in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: MLN9708 + Lenalidomide + Dexamethasone
Phases: Phase 1 / Phase 2
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: November 2011
Primary Completion: October 2013
17 Recruiting Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: November 2013
Primary Completion: June 2016
18 Recruiting Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Condition: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: Drug: MLN9708;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Thalidomide;   Drug: Lenalidomide
Phase: Phase 3
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: December 2012
Primary Completion: May 2018
19 Not yet recruiting MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Conditions: Multiple Myeloma;   Kahler Disease;   Plasma-Cell Myeloma;   Myelomatosis
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: MLN9708
Phase: Phase 1
Sponsor: Case Comprehensive Cancer Center
Study Start: May 2014
Primary Completion: July 2015
20 Recruiting Phase I Study of (Modified VXLD) Plus MLN9708 in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma
Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia;   Relapsed or Refractory Lymphoma
Interventions: Drug: MLN9708;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: PEG asparaginase;   Drug: Dexamethasone
Phase: Phase 1
Sponsor/Collaborators: Medical College of Wisconsin;   Ehab L Atallah
Study Start: October 2013
Primary Completion: December 2017

Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results
Indicates status has not been verified in more than two years